Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Oncology Venture hereby publishes a prospectus regarding the rights issue starting on April 17, 2019

Regulatory

The Board of Oncology Venture resolves to conduct a rights issue of new shares

Regulatory

Minutes of Ordinary General Meeting

Regulatory

Oncology Venture obtains option to in-license the European rights to the FDA approved ixabepilone

Regulatory

Dovitinib regulatory strategy confirmed and new combination biomarker DRP PD1/PD-L1 + dovitinib developed. Oncology Venture engages in partnering activities with Destum Partners

Regulatory

Laboratory set up in Berlin and strategic collaboration with leading German and Danish cancer coorporative groups entered to develop precision medicine for women’s cancers

Regulatory

Correction: Removal of the MAR plate in the release: The observation status of Oncology Venture is removed

Regulatory

The observation status of Oncology Venture is removed

Regulatory

Oncology Venture has established bridge loan facility

Regulatory

NOTICE TO CONVENE ORDINARY GENERAL MEETING

Regulatory

Oncology Venture publishes the Annual Report for 2018

Regulatory

Oncology Venture receives guarantees and undertakings for a proposed rights issue

Regulatory

Oncology Venture rearranges its financing agreement with EHGOS (Alpha Blue Ocean)

Regulatory

First patient dosed in a Phase 2 study with LiPlaCis in prostate cancer

Regulatory

Clinical update: Dovitinib DRP data mining successfully completed and new LiPlaCis data continues to support an FDA breakthrough designation strategy

Regulatory

Communique from EGM in Oncology Venture A/S

Regulatory

Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US

Regulatory

Oncology Ventures CEO Peter Buhl Jensen buys shares in the Company

Regulatory

Claus Frisenberg Pedersen, CCO in Oncology Venture buys shares in the Company

Regulatory

Claus Frisenberg Pedersen, CCO in Oncology Venture buys shares in the Company